Assetmark Inc. Increases Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Assetmark Inc. grew its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 11.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 62,802 shares of the medical equipment provider's stock after purchasing an additional 6,442 shares during the quarter. Assetmark Inc. owned approximately 0.09% of Lantheus worth $6,893,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. AlphaCentric Advisors LLC acquired a new position in Lantheus in the 3rd quarter valued at $988,000. Moloney Securities Asset Management LLC acquired a new position in shares of Lantheus in the third quarter valued at $1,066,000. Citizens National Bank Trust Department lifted its position in Lantheus by 2.4% during the third quarter. Citizens National Bank Trust Department now owns 12,798 shares of the medical equipment provider's stock worth $1,405,000 after purchasing an additional 298 shares during the period. Van ECK Associates Corp boosted its stake in shares of Lantheus by 58.6% in the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider's stock valued at $6,469,000 after purchasing an additional 21,604 shares in the last quarter. Finally, Harbor Capital Advisors Inc. lifted its position in shares of Lantheus by 56.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 128,913 shares of the medical equipment provider's stock worth $14,148,000 after purchasing an additional 46,262 shares during the period. Institutional investors own 99.06% of the company's stock.

Lantheus Price Performance

LNTH stock traded up $1.07 during midday trading on Tuesday, hitting $85.15. The company's stock had a trading volume of 1,791,305 shares, compared to its average volume of 1,002,962. The stock has a market capitalization of $5.92 billion, a P/E ratio of 13.99 and a beta of 0.51. The company's fifty day moving average price is $106.89 and its 200 day moving average price is $96.26. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on LNTH shares. StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Friday. JMP Securities dropped their price objective on Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a research note on Thursday, November 7th. Redburn Atlantic started coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price target for the company. Truist Financial restated a "buy" rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday. Finally, B. Riley raised their target price on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research report on Thursday, July 25th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $122.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.